During a live event, participating oncologists discuss the role of ctDNA and molecular testing in muscle-invasive bladder ...

Findings indicate that the test demonstrated 89.2% sensitivity and 87.8% specificity for detecting high-grade or invasive ...

The following is a summary of “GATA3 amplification is associated with high grade disease in non-invasive urothelial bladder cancer but unrelated to patient prognosis,” published in the February 2025 ...

Among patients with low-grade, intermediate-risk NMIBC, UGN-102 generated robust, durable responses in an analysis of the ...

Discover recent findings that highlight the potential for urinary DNA methylation testing to improve early detection and diagnosis of bladder cancer.

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S. bladder cancer patient registry at the 2025 American Society of Clinical ...

UGN-102 led to durable responses in low-grade, intermediate-risk bladder cancer, per phase 3 study findings at the 2025 ...

Determining an immunohistochemical profile to predict response to intravesical bacillus Calmette–Guérin (BCG) in patients with high-grade non-muscle invasive bladder cancer. This is an ASCO Meeting ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune ... In terms of safety, ...

Gene's lead asset shows high complete response rates in BCG-unresponsive NMIBC patients. Click here to read why ENGN stock is ...

The Bladder Cancer Company, announces the presentation on February 14 of a new abstract with study results from its U.S.